Immune-correlates analysis of an HIV-1 vaccine efficacy trial - sprookjes - yvandenbroek - TriplyDB

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

http://www.wikidata.org/entity/Q29617377

about

HIV-1 prophylactic vaccines: state of the art NK Cells in HIV Disease Approaches to preventative and therapeutic HIV vaccines Which New Health Technologies Do We Need to Achieve an End to HIV/AIDS?HIV-Host Interactions: Implications for Vaccine Design Harnessing the protective potential of HIV-1 neutralizing antibodies Recent update in HIV vaccine development The Significance of a Common Idiotype (1F7) on Antibodies against Human Immune Deficiency Virus Type 1 and Hepatitis C Virus Remodeling of the Host Cell Plasma Membrane by HIV-1 Nef and Vpu: A Strategy to Ensure Viral Fitness and Persistence Contrasting Adult and Infant Immune Responses to HIV Infection and Vaccination Immune correlates of vaccine protection against HIV-1 acquisition Conformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1 Evaluation of Candidate Biomarkers of Type 1 Diabetes via the Core for Assay Validation A New Scientific Paradigm may be Needed to Finally Develop an HIV Vaccine Sieve analysis in HIV-1 vaccine efficacy trials Nonhuman primate models for HIV/AIDS vaccine development Designing synthetic vaccines for HIV Antibody responses to envelope glycoproteins in HIV-1 infection Design Challenges for HIV-1 Vaccines Based on Humoral Immunity Poxvirus vectors as HIV/AIDS vaccines in humans HIV-1 neutralizing antibodies: understanding nature's pathways Induction of intestinal immunity by mucosal vaccines as a means of controlling HIV infection Vaccines for the 21st century Mother-infant HIV transmission: do maternal HIV-specific antibodies protect the infant?Antibodies in HIV-1 vaccine development and therapy HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design Challenges in mucosal HIV vaccine development: lessons from non-human primate models A global approach to HIV-1 vaccine development Virological features associated with the development of broadly neutralizing antibodies to HIV-1 A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen COMPASS identifies T-cell subsets correlated with clinical outcomes DNA and protein co-immunization improves the magnitude and longevity of humoral immune responses in macaques Shaping T cell - B cell collaboration in the response to human immunodeficiency virus type 1 envelope glycoprotein gp120 by peptide priming Mucosal B Cells Are Associated with Delayed SIV Acquisition in Vaccinated Female but Not Male Rhesus Macaques Following SIVmac251 Rectal Challenge Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques Antigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cells Molecular evolution of broadly neutralizing Llama antibodies to the CD4-binding site of HIV-1 Elimination of HIV-1-infected cells by broadly neutralizing antibodies ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge Capsid-Targeted Viral Inactivation: A Novel Tactic for Inhibiting Replication in Viral Infections

P2860

Q26740042-1409B400-B3E8-4409-A8E0-547A92231C80 Q26752833-23DEFF78-8109-4765-9AF3-89C7BBB38F99 Q26764851-8FBA4733-691D-47B7-A043-4384FB403921 Q26765043-65AA31EE-0113-4797-8308-AADAD86A2F64 Q26765966-9F685105-747C-4B07-B7D3-AEA4BDCC0EEF Q26766153-99E29727-6873-404F-AF5D-8A00A9BE22B0 Q26766628-A0D0CBE5-2FBA-4F0C-B543-9D477220489B Q26767258-9DF8C2C9-2C42-4B1B-8317-2F185F853799 Q26767362-7BC1F860-8AD9-4D32-B0CF-DB226526C501 Q26776518-D3738CBE-58C0-4933-B1EB-E0EA6CCB71FA Q26778573-9A4A5025-765D-4557-8352-16AA3BF634F6 Q26782237-0021BB47-124B-4F73-87F3-1DA3C6C3FAC4 Q26783728-A136EB89-75F9-4736-9C54-B934868C53FA Q26830360-4C692CA1-D7EA-4A6C-B4A4-02DF01F976A7 Q26851376-87C8D363-AB5C-47AC-B2A6-D168FC25C1E0 Q26861148-D880E4F6-5090-4B3E-ACC8-9C81C49EF843 Q26862617-E87B87AC-EC28-48D1-9577-615F2FC8071C Q26991572-BE48D120-7A26-49B3-88AA-4AA94914DB49 Q26991829-A9A76E71-B9F6-4665-9CEB-36FCDCC4619F Q26995078-4785F5E5-F6A9-478F-BF74-864F3E02609F Q27000480-6DA5C08D-DA40-4D47-B7BA-D2B99947842F Q27001897-1FA58A33-3357-495A-9556-6E2F5F379C0B Q27007529-9F427628-E07D-42EA-895D-796034683545 Q27008774-FD2E9A38-49D3-4BB1-86E1-EC04AE8CA399 Q27011574-0541778C-E122-4604-90A2-49436143C9EF Q27022055-4F350E06-CE98-4A2F-B3B1-C1DCB3942924 Q27022152-11EDB709-8564-4770-AE49-A2C017108C80 Q27024614-2FFC0442-FA1B-4E28-9596-72BEED1F814B Q27025177-CAE33453-7F8F-41C6-8072-5AE57050F10E Q27302081-3FA987BA-F3DA-4D12-A698-6A8BF17FB8CE Q27314516-ED7B9914-1DAD-4DA9-8CEE-B99E620AB4E1 Q27316075-A4FD706D-1A80-45A1-B706-33F82BF597AB Q27316280-AC02670E-3023-477B-859E-DCB81DE7CAD2 Q27318151-825E00EC-88A4-49A3-936A-7474A6C40F1F Q27318508-97BA55FF-2441-4D17-B006-1B0794003696 Q27320687-57DBA026-ECEB-4C5F-8207-70968F6AA307 Q27322403-0B7B8FA4-6E8F-4922-8E46-D50D9B6F6382 Q27329126-5F373A1A-A586-4450-8A2B-E4F96BCAADC1 Q27342615-14E9FD02-3030-4C72-8C67-01882BB00433 Q27468669-E53F2F05-074F-46D6-AD15-7EAC9689456F

P2860

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

http://www.wikidata.org/entity/Q29617377

description

2012 nî lūn-bûn

@nan

2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

@ast

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

@en

type

label

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

@ast

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

@en

prefLabel

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

@ast

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

@en

P1433

Q29617377-32B1B444-E04A-4542-B4DE-15EE169F6FAF

P1476

Q29617377-B7AE8BF7-A478-442E-A7ED-01524181120D

P2093

Q29617377-074390CD-10B6-45B1-A04F-2C0A48CC5AC2

Q29617377-0909C864-9ED0-4D88-A248-244D4AD30818

Q29617377-17E15491-B609-4957-B743-1F708789F69F

Q29617377-18F2D0A2-25E3-4977-80F8-9F62B5B0BAF9

Q29617377-228D0290-BAC0-4C31-BECE-CB0D98C4C930

Q29617377-27AE7DE4-CE08-425B-B948-321AAED4A671

Q29617377-2A91BA5F-B434-4254-B5F6-44261A7E8941

Q29617377-3367441D-872D-443F-8A5F-46AD0F3DA9D2

Q29617377-356B41B3-95DE-4616-B619-947DCBF390FB

Q29617377-46966505-A2C1-490E-8B46-EC70EDB6D3E8

P2860

Q29617377-0D5C40B9-6AAD-4298-91AC-DB68A0099DA6

Q29617377-189731B7-B18C-4D86-B818-5FDDD87928FE

Q29617377-2041E086-8B5E-4FB2-9A50-A69DAD445FA7

Q29617377-4DF8F529-D5D0-4D54-B9D7-68E80724E840

Q29617377-4E3B57F0-E4C1-43DE-83DC-75565BDAD024

Q29617377-64252AC2-8E8F-48FA-AC28-F71016BD86E0

Q29617377-764C2749-06CF-45FF-81A6-87DEFFCABCDF

Q29617377-7F296214-940B-44EE-B61A-54231858B88E

Q29617377-80E9CB47-5B8E-4E0D-AB8F-E63AC2FE433D

Q29617377-824E3A58-169C-44F3-B3AA-445B1C053BF4

P304

Q29617377-6429876D-9EE4-48A3-8AFC-6B1512E806BD

P31

Q29617377-29FBFE5D-8A4A-4BCA-9F69-9CB7E5C792D3

P3181

Q29617377-FDD50F0F-1605-43AB-AC2F-3E7D2F41095A

P356

Q29617377-52440B72-4375-4E86-8591-09671430A217

P407

Q29617377-3C7CCBF5-2DCC-44FE-AE24-59759F440B53

P433

Q29617377-8E333AC1-954C-443C-A444-9E88287A3D9E

P478

Q29617377-DF96B69A-5D19-430C-AA6B-4E0891218FB5

P50

Q29617377-02FAE5EF-ECAA-4262-B88F-C3741CC99BAB

Q29617377-13B221EE-C87B-454D-974F-7950E3325081

Q29617377-263BD0A7-31E6-4845-9D8C-6A86CB962797

Q29617377-2E1FAEC7-1668-43E6-BBB9-0429369EC695

Q29617377-A517ED0D-AE69-40CD-B9D0-314F42D485C3

Q29617377-BB84F8EF-BB91-454D-850C-69EB4D8AB61D

Q29617377-C1C31931-C222-49D7-9BDA-735890CACBD8

P5008

Q29617377-8A289A19-5B29-4511-84BB-DFF774057199

P577

Q29617377-DDB16EE4-029F-4D6D-AC7B-A992F012DBD9

P5875

Q29617377-4B320AAB-8291-40D3-9A48-5ED9D530B880

P698

Q29617377-58D3FEB9-EE33-4797-854D-FF051935D1CA

P921

Q29617377-f3c11aed-483a-10a3-df8c-da1e8a19e407

P932

Q29617377-4431C311-54D8-4C48-98E7-3230B487A3FC

P3181

P356

P1433

The New England Journal of Medicine

P1476

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

@en

P2093

Abraham Pinter

http://www.w3.org/2001/XMLSchema#string

Allan DeCamp

http://www.w3.org/2001/XMLSchema#string

Anthony L DeVico

http://www.w3.org/2001/XMLSchema#string

Barton F Haynes

http://www.w3.org/2001/XMLSchema#string

Charla Andrews

http://www.w3.org/2001/XMLSchema#string

Chitraporn Karnasuta

http://www.w3.org/2001/XMLSchema#string

Constance Williams

http://www.w3.org/2001/XMLSchema#string

David C Montefiori

http://www.w3.org/2001/XMLSchema#string

David T Evans

http://www.w3.org/2001/XMLSchema#string

Erik Billings

http://www.w3.org/2001/XMLSchema#string

P2860

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

Crystal Structure of Human Antibody 2909 Reveals Conserved Features of Quaternary Structure-Specific Antibodies That Potently Neutralize HIV-1

Elite control of HIV Infection: implications for vaccines and treatment

No adjustments are needed for multiple comparisons

Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

The genotype of early-transmitting HIV gp120s promotes α (4) β(7)-reactivity, revealing α (4) β(7) +/CD4+ T cells as key targets in mucosal transmission.

Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant

P304

1275-1286

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

244764

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA1113425

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

366

http://www.w3.org/2001/XMLSchema#string

P50

Jaranit Kaewkungwal

Supachai Rerks-Ngarm

P5008

P577

2012-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

223957492

http://www.w3.org/2001/XMLSchema#string

P698

22475592

http://www.w3.org/2001/XMLSchema#string

P921

P932

3371689

http://www.w3.org/2001/XMLSchema#string